AZN: financial statements from SEC — TradeAlmanac

AZN

AstraZeneca PLC: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022
Revenue	58.74B	54.07B	45.81B	44.35B
Cost of revenue	10.63B	10.21B	8.27B	12.39B
Gross profit	48.11B	43.87B	37.54B	31.96B
Research and development	14.23B	13.58B	10.94B	9.76B
Selling, general and administrative	19.93B	19.98B	19.22B	18.42B
Operating income	13.74B	10.00B	8.19B	3.76B
Pre-tax income	12.40B	8.69B	6.90B	2.50B
Income tax	2.17B	1.65B	938M	−792M
Net income	10.23B	7.04B	5.96B	3.29B
Earnings per share	6.60	4.54	3.84	2.12
Earnings per share, diluted	6.54	4.50	3.81	2.11
Weighted average shares	1.55B	1.55B	1.55B	1.55B

Balance sheet

Metric	18 Aug 2026	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022	31 Dec 2021
Cash and equivalents	—	5.71B	5.49B	5.84B	6.17B	—
Receivables	—	15.18B	12.97B	12.13B	10.52B

Cash flow

Metric	31 Dec 2025	31 Dec 2024	31 Dec 2023	31 Dec 2022
Operating cash flow	14.58B	11.86B	10.35B	9.81B
Capital expenditure	2.81B	1.92B	1.36B	1.09B
Investing cash flow	−6.81B	−7.98B	−4.06B	−2.96B
Dividends paid

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator